Skip to main content

Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)

Tipranks - Tipranks - Wed Mar 4, 6:30AM CST

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks, with a price target of $47.00.

Claim 70% Off TipRanks Premium

Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Exelixis, and Insmed. According to TipRanks, Willey has an average return of 7.6% and a 42.39% success rate on recommended stocks.

In addition to Stifel Nicolaus, Zymeworks also received a Buy from LifeSci Capital’s Charles Zhu in a report issued yesterday. However, on the same day, TipRanks – OpenAI reiterated a Hold rating on Zymeworks (NASDAQ: ZYME).

See the top stocks recommended by analysts >>

Based on Zymeworks’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $41.21 million. In comparison, last year the company earned a revenue of $31.03 million and had a GAAP net loss of $23.51 million

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).